glp 1 agonisté A Closer Look at the Dermatological Profile of GLP-1 Agonists Schematic illustration of monoagonists, dual

June 2026 Update: GLP-1 Constipation Supply Status We are actively monitoring the supply of OTC osmotic, stimulant laxatives & stool softeners

M.ZhaoS.LeeG

The median interval between the bariatric procedure and the initiation of pharmacological treatment was 5 years (IQR: 27 years)

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

Holst et al

1-8 Recent European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes state that GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide extended release [ER], dulaglutide, efpeglenatide) should be considered for glucose-lowering treatment in patients with T2D at risk of or with heart failure (HF